Sarepta Therapeutics, Inc. (SRPT)
16.69
+0.04
(+0.24%)
USD |
NASDAQ |
Mar 20, 16:00
16.73
+0.04
(+0.24%)
After-Hours: 20:00
Sarepta Therapeutics Research and Development Expense (Quarterly) : 319.50M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Keros Therapeutics, Inc. | 17.83M |
| Merck & Co., Inc. | 2.499B |
| PTC Therapeutics, Inc. | 133.13M |
| REGENXBIO, Inc. | 55.74M |
| Gilead Sciences, Inc. | 1.565B |